Effect of nobivolol on serum diabetic marker and lipid profile in normal and streptozotocin-nicotinamide induced diabetic rats

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Volumn 1, Issue 2, 2010, Pages 329-334

  Kakadiya, Jagdish ^a   Shah, Mehul ^a   Shah, N J ^a  

^a Dharmaj Degree Pharmacy College   (India)

Author keywords

HbA1c; Lipid profile; Nicotinamide; Nobivolol; Streptozotocin

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NEBIVOLOL; NICOTINAMIDE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

RATTUS;

EID: 79952599021     PISSN: None     EISSN: 09758585     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Kahn SE, Porte DJ. The pathophysiology of type II (noninsulin-dependent) diabetes mellitus: Implications for treatment. In: Rifkin H, Porte DJ, eds. Ellenberg and Rijkin's Diabetes Mellitus: Theory and Practice. New York: Elsevier Science 1990:436-456.
2. Leibowitz HE. Oral hypoglycemic agents. In: Rifkin H, Porte DJ, eds. Ellenberg nd Rijkin's Diabetes Mellitus: Theory and Practice. New York: Elsevier Science 1990:554-574.
3. Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli M, Ribes G. Diabetes 1998; 47:224-229.
4. Paulsen EP. Metabolism 1973; 22: 269-271.
5. Koening RL, Peterson CM, Jones RL, Saudek C, Lehrman M and Cerami A. New Eng J Med 1976; 295: 417-420.
6. Gabbay KH. New Eng J Med 1976; 95: 443-454.